Clinical Trial Update: Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and efficacy of KX2-391 in bone-metastatic, castration-resistant prostate cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone-metastatic Castration-resistant Prostate Cancer

Drugs mentioned

• KX2-391

Snippet

Sponsor: Athenex, Inc. | Conditions: Bone-Metastatic, Castration-Resistant Prostate Cancer | Phase 2 | Status: COMPLETED